CCL5/CCR5基因启动子多态性与糖尿病性微血管并发症的相关性评估

Association between CCL5/CCR5 Gene Promoter Polymorphism and Diabetic Microvascular Complications

目的更准确地评估趋化因子配体5(CCL5)/趋化因子受体5(CCR5)基因启动子多态性与糖尿病性微血管并发症(DMI)之间的关联。方法通过PubMed、Embase、Medline、中国国家知识基础设施、Web of Science和Cochrane数据库检索相关研究文献。应用合并的优势比(OR)和95%置信区间(CI)描述CCL5-403 G/A、CCL5-28 C/G、CCR5-59029 G/A与DMI关联的强度。结果数据包括2737例DMI患者和2435例糖尿病对照受试者。CCL5-403 G/A和CCL5-28 C/G多态性与DMI风险没有显著相关。在显性模型中,CCR5-59029 G/A是DMI的独立危险因素(OR为1.77;95%CI为1.06,2.97)。亚洲人出现CCR5-59029A阳性基因型的风险显著(OR为2.08;95%CI为1.68,2.57)。此外,CCR5-59029A阳性基因型与白蛋白尿风险增加相关(微量白蛋白尿OR为1.68;95%CI为1.15,2.44;大量蛋白尿OR为2.70;95%CI为1.07,6.83)。结论CCL5基因启动子多态性与DMI的风险没有关联。但是,CCR5-59029A多态性会影响个体对DMI的敏感性。

Objective To evaluate the association between the promoter polymorphism of chemokine ligand 5(CCL5)/chemokine receptor 5(CCR5)gene and diabetic microvascular complications(DMI).Methods PubMed,Eemase,Medline,National Knowledge Infrastructure of China,Web of Science and Cochrane databases were used to search the related research literature.Combined odds ratio(OR)and 95%confidence interval(CI)were used to describe the strength of association between DMI and CCL5-403 G/A,CCL5-28 C/G and CCR5-59029 G/A.Results Data included 2737 patients with DMI and 2435 diabetic control subjects.CCL5-403 G/A and CCL5-28 C/G polymorphisms were not significantly associated with DMI risk.In the dominant model,CCR5-59029 G/A was an independent risk factor for DMI(OR=1.77;95%CI:1.06,2.97).The risk of CCR5-59029A positive genotype in Asians was significant(OR=2.08;95%CI:1.68,2.57).In addition,CCR5-59029A positive genotype was associated with increased risk of albuminuria(Microalbuminuria OR=1.68;95%CI:1.15,2.44.The macroalbuminuria OR=2.70;95%CI:1.07,6.83).Conclusion CCL5 gene promoter polymorphism is not associated with DMI risk.However,CCR5-59029A polymorphism may affect the susceptibility of individuals to DMI.